Kymera Therapeutics, Inc. financial data

Symbol
KYMR on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
500 North Beacon Street, 4 Th Floor, Watertown, MA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2024 - Oct 31, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 753 % +18.7%
Debt-to-equity 23.1 % -27.4%
Return On Equity -25 % +33.6%
Return On Assets -20.3 % +28.9%
Operating Margin -229 % +42.1%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 64.8M shares +16.7%
Common Stock, Shares, Outstanding 64.7M shares +16.8%
Entity Public Float 1.01B USD +27.9%
Common Stock, Value, Issued 7K USD +16.7%
Weighted Average Number of Shares Outstanding, Basic 76.1M shares +30.3%
Weighted Average Number of Shares Outstanding, Diluted 76.1M shares +30.3%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 87.6M USD +86.9%
Research and Development Expense 221M USD +23.5%
General and Administrative Expense 61.4M USD +17.1%
Operating Income (Loss) -200M USD -8.3%
Income Tax Expense (Benefit) 200K USD
Net Income (Loss) Attributable to Parent -167M USD -0.01%
Earnings Per Share, Basic -2.34 USD/shares +18.2%
Earnings Per Share, Diluted -2.34 USD/shares +18.2%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 111M USD +36.6%
Accounts Receivable, after Allowance for Credit Loss, Current 0 USD
Assets, Current 569M USD +51.4%
Property, Plant and Equipment, Net 51.2M USD +41.8%
Operating Lease, Right-of-Use Asset 48.1M USD -12.5%
Other Assets, Noncurrent 0 USD -100%
Assets 1.03B USD +87.3%
Accounts Payable, Current 6.49M USD +30.5%
Accrued Liabilities, Current 26.5M USD +0.56%
Contract with Customer, Liability, Current 20M USD -26.8%
Liabilities, Current 66.5M USD +5.33%
Contract with Customer, Liability, Noncurrent 0 USD -100%
Operating Lease, Liability, Noncurrent 73.6M USD -3.88%
Other Liabilities, Noncurrent 0 USD -100%
Liabilities 142M USD -9.52%
Accumulated Other Comprehensive Income (Loss), Net of Tax 1.93M USD
Retained Earnings (Accumulated Deficit) -684M USD -32.4%
Stockholders' Equity Attributable to Parent 893M USD +126%
Liabilities and Equity 1.03B USD +87.3%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -39.6M USD +9.96%
Net Cash Provided by (Used in) Financing Activities 354M USD +30423%
Net Cash Provided by (Used in) Investing Activities -331M USD -1445%
Common Stock, Shares Authorized 150M shares 0%
Common Stock, Shares, Issued 64.7M shares +16.8%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -16.4M USD +9.78%
Interest Paid, Excluding Capitalized Interest, Operating Activities 49K USD -5.77%
Deferred Tax Assets, Valuation Allowance 162M USD +35.2%
Deferred Tax Assets, Gross 184M USD +46.3%
Operating Lease, Liability 85.1M USD +7.52%
Depreciation 6.3M USD +80%
Payments to Acquire Property, Plant, and Equipment 7.4M USD +84.6%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -163M USD +0.55%
Lessee, Operating Lease, Liability, to be Paid 128M USD +0.01%
Property, Plant and Equipment, Gross 65.3M USD +43%
Operating Lease, Liability, Current 11.5M USD +345%
Lessee, Operating Lease, Liability, to be Paid, Year Two 12.4M USD +2.42%
Lessee, Operating Lease, Liability, to be Paid, Year One 12.1M USD +5.03%
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 42.7M USD -12.2%
Lessee, Operating Lease, Liability, to be Paid, Year Three 12.8M USD +2.42%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 13.2M USD +2.42%
Depreciation, Depletion and Amortization 1.46M USD +66.2%
Deferred Tax Assets, Net of Valuation Allowance 21.7M USD +278%
Share-based Payment Arrangement, Expense 52.1M USD +26.7%